RNAZ
Transcode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.71
−0.58%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.00
From 52W high−88.77%
Volume26296.00
Market cap$28.95M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.00
From 52W high
−88.77%
Volume
26296.00
Market cap
$28.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
P/E (TTM)
—
RSI (14)
25.3
MomentumView details →
1D Return
−0.58%
YTD Return
−74.52%
SummaryUpdated Jun 1, 2026
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Boston, Massachusetts. The company went public in July 2021 and focuses on developing innovative RNA-based therapeutics and diagnostics specifically targeting metastatic cancer. TransCode operates in the highly specialized field of precision oncology, utilizing advanced RNA interference (RNAi) and gene editing technologies to address one of cancer's most challenging aspects - metastasis, which occurs when cancer cells spread from their original location to other parts of the body.
Similar companies
Latest newsMore news →
TransCode Therapeutics announced the retirement of its Chief Financial Officer Tom Fitzgerald and the appointment of John Tattory as Interim Chief Financial Officer.10d agoTransCode Therapeutics announced the publication of a peer-reviewed article in Cancers reporting that its lead therapeutic candidate TTX-MC138 produced significant survival benefits in a preclinical model of breast cancer bone metastasis.20d ago